Curcumin in Combination With Mesalamine Induces Remission in Patients With Mild-to-Moderate Ulcerative Colitis in a Randomized Controlled Trial

Lang, Alon; Salomon, Nir; Wu, Justin C.Y.; Kopylov, Uri; Lahat, Adi; Har-Noy, Ofir; Ching, Jessica Y. L.; Cheong, Pui Kuan; Avidan, Benjamin; Gamus, Dorit; Kaimakliotis, Ioannis; Eliakim, Rami; Ng, Siew C.; Ben‐Horin, Shomron

doi:10.1016/j.cgh.2015.02.019

Cited by 333 publications

(211 citation statements)

References 25 publications

Supporting

Mentioning

196

Contrasting

Unclassified

Order By: Relevance

“…Moreover, curcumin supplement did not produce any adverse effects (Lang et al, 2015). Another study highlights the potential effect of curcumin in knee osteoarthritis (OA) patients.…”

Section: Some Clinical Trials With Curcuminmentioning

confidence: 94%

The beneficial role of curcumin on inflammation, diabetes and neurodegenerative disease: A recent update

Ghosh

Banerjee

Sil

2015

Food and Chemical Toxicology

417

242

View full text Add to dashboard Cite

“…Moreover, curcumin supplement did not produce any adverse effects (Lang et al, 2015). Another study highlights the potential effect of curcumin in knee osteoarthritis (OA) patients.…”

Section: Some Clinical Trials With Curcuminmentioning

confidence: 94%

The beneficial role of curcumin on inflammation, diabetes and neurodegenerative disease: A recent update

Ghosh

Banerjee

Sil

2015

Food and Chemical Toxicology

417

242

View full text Add to dashboard Cite

“…A random blind study with 207 patients over 8 weeks showed curcumin to be beneficial for IBS patients, but the study did not contain a placebo control [55] . In 2 independent random double-blind placebo controlled studies, combined therapy with curcumin and mesalamine was superior over mesalamine alone [56,57] . In 2 small open studies curcumin showed marginal efficacy for IBD in adult and pediatric patients [58,59] .…”

Section: Curcuminmentioning

confidence: 99%

Antioxidant Supplements and Gastrointestinal Diseases: A Critical Appraisal

2017

View full text Add to dashboard Cite

The gastrointestinal tract digests and absorbs dietary nutrients, protects the body against physical and chemical damage from contents in its lumen, provides immunity against external antigens, and keeps an optimum environment for the gut microbiota. These functions cannot be performed normally in several diseases of which the following are discussed here: irritable bowel syndrome and inflammatory bowel disease, which includes Crohn's disease and ulcerative colitis. Because these diseases are associated with oxidative stress, a host of antioxidant supplements are used for maintenance and recovery of the gut functions. However, the benefits of these supplements have not been established. The available 80 human trials were rated for levels of confidence and for benefits of the antioxidant supplements. For Crohn's disease, the supplements for which clear benefits occurred in at least 2 studies were allopurinol, Boswellia serrata (frankincense or shallaki), Artemesia species (wormwood), Tripterygium wilfordii (léi gōng téng), and omega-3 fatty acids. Similar beneficial supplements for ulcerative colitis were allopurinol, Matricaria chamomilla (chamomile), Curcuma longa (curcumin in turmeric), and omega-3 fatty acids. There was also a clear benefit for ulcerative colitis in 2 studies where a multiherbal Chinese medicine preparation and an Ayurvedic medicine preparation were used. For irritable bowel syndrome, there was only a marginal benefit of some of the antioxidant supplements. Thus, some antioxidant supplements may be beneficial at certain stages of specific diseases. This is consistent with the current concept that antioxidants act by inhibiting oxidative stress pathways in a tissue- and environment-specific manner and not by simply acting as scavengers.

show abstract

“…Curcumin is a natural phytochemical derived from the Indian spice turmeric and has been widely used for centuries in inflammatory diseases. Two recent randomized, placebo-controlled trials have demonstrated that curcumin was superior to placebo in inducing and maintaining remission in patients with mild-tomoderate active UC [41,42] . Thalidomide is a small molecule with anti-tumor necrosis factor α, immunomodulatory and antiangiogenic properties.…”

Section: Out Of the Box Agents For Ibdmentioning

confidence: 99%

The Future of IBD Therapy: Where Are We and Where Should We Go Next?

Mao

2016

Dig Dis

View full text Add to dashboard Cite

Background: The advent of biologic agents opens up a new era for the treatment of inflammatory bowel disease (IBD). In this era, the treatment goal has evolved from the traditional goal of clinical remission to a combination of clinical remission, laboratory normalization and mucosal healing, designated as ‘complete deep remission'. Such complete deep remission comprises a more ambitious disease control strategy that is believed to probably modify the natural course of IBD. Key Messages: To achieve this goal, optimization of current strategy and introduction of novel therapies have gained significant interest. In this concise review, we aim to provide an overview of the current status and future direction of IBD treatment. Specifically, we will describe the application of personalized therapy, development of new biologics, intestinal microbiome manipulation and out-of-the-box agents for IBD. Conclusions: More evidence is still desirable to better optimize the current treatment and apply novel biologics. Personalized medicine has the potential to optimize efficacy, decrease the risk of adverse events and minimize costs and should be proposed as a standard of care for the management of IBD.

show abstract

Curcumin in Combination With Mesalamine Induces Remission in Patients With Mild-to-Moderate Ulcerative Colitis in a Randomized Controlled Trial

Cited by 333 publications

References 25 publications

The beneficial role of curcumin on inflammation, diabetes and neurodegenerative disease: A recent update

The beneficial role of curcumin on inflammation, diabetes and neurodegenerative disease: A recent update

Antioxidant Supplements and Gastrointestinal Diseases: A Critical Appraisal

The Future of IBD Therapy: Where Are We and Where Should We Go Next?

Contact Info

Product

Resources

About